

News Release

Lonza Group Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
www.lonza.com

Lonza and CELLution Biotech enter into long-term agreement

Basel & Verviers, 19 February 2008 – Lonza and CELLution Biotech enter into a strategic partnership in the area of single use bioreactors. The two parties have signed an exclusive global sales and distributor agreement related to the CELL-tainer[®] developed by CELLution Biotech. With this agreement Lonza obtains the global and exclusive marketing and sales rights for the CELL-tainer[®].

The CELL-tainer[®] is a single use bioreactor with non-invasive sensors. It has an advanced mixing technology and novel, expandable processing volume within the same reactor run. These features will give the biopharmaceutical industry higher product yields in mammalian cell based processes. Due to its superior gas exchange properties the CELL-tainer[®] is also suited for microbial culture. In addition, the linear scalability of this novel system will shorten the process development time of mammalian and microbial produced biopharmaceuticals significantly. The 20L CELL-tainer[®] will be mainly used in process development and pre-clinical production. The larger CELL-tainer[®], which will be launched later, could be used for the manufacturing of later stage clinical trial material and commercial productions.

“Lonza is pleased to enter into this agreement with CELLution Biotech. The CELL-tainer[®] bioreactor system complements the Lonza Bioscience Flexible Packaging product range, offering our clients higher cell densities and higher productivity with cell cultures. In addition the CELL-tainer[®] bags are made from Lonza’s proprietary Platinum UltraPAK™ film material”, said Roel Gordijn, Global Sales & Marketing Director for the business unit Media at Lonza Bioscience.

“Lonza’s expertise in biopharmaceutical manufacturing and medium development together with CELLution Biotech’s unique single use bioreactor will enable customers to get the maximum out of their processes” said Nico Oosterhuis, CSO at CELLution Biotech.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found at: www.lonza.com.

About CELLution

CELLution Biotech BV is developing technologies and designing tools for application in single-use bioreactor systems. Further information can be found at: www.cellutionbiotech.com.

For further Information:

Head Corporate Communications

Janet White

Tel +41 61 316 8566

Fax +41 61 316 9566

janet.white@lonza.com

Media Relations

Dominik Werner

Tel +41 61 316 8798

Fax +41 61 316 9798

dominik.werner@lonza.com

Investor Relations

Alexandre Pasini

Tel +41 61 316 8835

Fax +41 61 316 9835

alexandre.pasini@lonza.com

CELLution Biotech BV

Cereslaan 2

9641MJ Veendam

The Netherlands

Hans van den Berg

Director Marketing and Sales

Tel: +31 6 1379 8835

hans@cellutionbiotech.com